The Supply of a licensed factor IX gene therapy
Details
| Contract Title: | The Supply of a licensed factor IX gene therapy |
| Published Date: | Apr 2, 2025 |
| Notice Type: | Award (ContractAwardNotice) |
| Value Banding: | High Value |
| Delivery Point: | Ireland |
Description:
People with severe or moderately-severe factor IX deficiency are at risk of severe, life threatening bleeding unless factor IX is replaced. The current method of treatment is to replace factor IX using factor IX clotting factor concentrate which is given intravenously on a regular weekly schedule (prophylaxis). The current standard of care for people with severe or moderately-severe factor IX deficiency in Ireland is that all patients are treated with factor IX prophylaxis. Despite regular p...